As theBRAF V600Emutation has also been described in melanomas and the treatment with MEK and BRAF inhibitors has drastically changed the evolution of that disease, MEK and BRAF inhibitors have also been considered for treatment of selected PCPs. This evidence concerns the gene MAP2K7 and melanoma.